study was carried to find the role and safety of ondansetron, dexamethasone and ondansetron plus dexamethasone in preventing PONV in patients undergoing ...
Aug 21, 2013 - David C. Mohr*, Jenna Duffecy, Joyce Ho, Mary Kwasny, Xuan Cai, Michelle Nicole Burns, Mark Begale. Center for Behavioral Intervention ...
Oct 25, 2011 - The Annals of Pharmacotherapy □. 2011 November ... The use of pictograms on medication vials as a means of improving patients' understanding of ... Paul's Hospital ambulatory pharmacy meet with clinical pharmacists ...
Apr 7, 2008 - Dethloff T, Tofteng F, Frederiksen HJ, Hojskov M, Hansen BA, ... Tofteng, Hans-Jorgen Frederiksen, Michael Hojskov, Bent Adel Hansen,.
Feb 19, 2013 - cleansers and provide the evidence for health care professionals to ... the Association of Women's Health, Obstetric and Neonatal Nurses. 203 ...
[Downloaded free from http://www.njms.in on Monday, May 28, 2018, IP: 186.178.174.26] ...... Beckett AH, Stenlake JB. Ultraviolet visible absorption.
Oct 2, 2012 - men in the pooled video condition were significantly more likely than ... Effective, brief HIV prevention interventions featuring digital media that ...... sores: the making and evaluation of a successful social marketing campaign.
David H. Winslow, MD1; Charles H. Bowden, MD2; Karen P. DiDonato, RN, MSN2; Pamela A. McCullough, PhD1 ...... Magill RA, Waters WF, Bray GA, et al.
Keywords: affect, energy healing, mental boundaries, personality, ...... 91 exploration. The Journal of Alternative and Complementary Medicine,. 11(3), 569-574.
Sep 22, 2004 - Quality of Life Brief Questionnaire, which was completed at baseline and at the end of the ... Hindi translation of the WHOQOLâBREF was used.
Aug 2, 2013 - and lipodermatosclerosis of the affected limb. The body mass index (BMI) was calculated for all patients. According to international norms, a ...
of symptoms consistent with active TB after beginning IPT, and are currently ..... evaluated by two ELISAs run in parallel (Ortho Kit HIV-1 and HIV-2 or Abbot ...
May 5, 2018 - (2) Vinotha Sanmugarajah, University of Jaffna, Sri Lanka. ... of the knee according to the criteria established by the American College of.
Jul 26, 2013 - obesity-related sleep disorders in men: study protocol for a .... mice with gut microbiota compared with their germ-free ... included cardiac and musculoskeletal status evaluations, ... (Nordic sleep disorder questionnaire, Epworth Sle
been used successfully for socket preservation pro- cedures.5,6 However, each bone substitute displays a different resorption rate. Clinicians should be aware ...
leukotriene receptor antagonist zafirlukast versus placebo in patients with allergic rhinitis during the .... corticoids in any form within 2 wk prior to the inclusion visit. ..... vance of histamine and leukotrienes C4 and B4 in grass pollen-induced
Eliane M. S. Leyten,6 Tania Mudrikova,7 Kees Brinkman,8 Jan G. den Hollander,9 ..... Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired.
ing Filemaker Pro version 7.0v1 (FileMaker Inc., Santa Clara,. CA). SPSS version 14.0.0 software (SPSS Inc., Chicago, IL) was then used to conduct statistical ...
the sacroiliac joints, the symphysis pubis, or mm. gluteus maximus/medius. Exclusion criteria. Earlier experience of acupuncture treatment. Fear of needles.
COPYRIGHT PULSUS GROUP INC. â DO NOT COPY. Pain Res ... National Opioid Use Guideline Group, in collaboration with most provincial Colleges of ...
Nov 24, 2014 - spectrums ranging from 100 to 4,000 kHz are and have been available for the clinical practice [3, 14, 16]. In 1998, Li et al. first described a ...
Jul 7, 2014 - in childhood (2 to 3 per 1000 live births), and is frequently accompanied by ... subtypes and within the same subtype; for example in children with the ... with CP but one study reports that children with spastic diplegic CP do .... (th
Objectives: The aim of the study was to compare the efficacy and safety of induction with the addition of enfuvirtide to a newly designed oral, highly active ...
Journal of Antimicrobial Chemotherapy (2008) 62, 1374– 1378 doi:10.1093/jac/dkn377 Advance Access publication 8 September 2008
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study Bonaventura Clotet1*, Amedeo Capetti2, Luis E. Soto-Ramirez3, Jose M. Gatell4, Lucy Rowell5, Miklos Salgo6 and Jonathan M. Schapiro7 1
Received 27 May 2008; returned 28 June 2008; revised 31 July 2008; accepted 10 August 2008 Objectives: The aim of the study was to compare the efficacy and safety of induction with the addition of enfuvirtide to a newly designed oral, highly active antiretroviral therapy (HAART) regimen versus HAART alone followed by a maintenance phase wherein participants were randomized to either continue/discontinue enfuvirtide while maintaining HAART or continue HAART alone (NCT00487188). Methods: Participants with HIV-1 RNA 1000 copies/mL, CD4 count 200 cells/mm3 and genotype sensitivity score 2 (excluding enfuvirtide) were randomized 2:1 to enfuvirtide1HAART or HAART alone and assessed every 4 weeks. Participants achieving
